Logo

SLXN

Silexion Therapeutics Ltd.

SLXN

Silexion Therapeutics Ltd. • NASDAQ
$2.83 ▼ -2.08% (-0.06)
Market Cap $1.59 M
52w High $63.45
52w Low $2.13
Dividend Yield 0%
P/E 0.01
Volume 24.74K
Outstanding Shares 560.96K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $3.288M ▲ $-3.262M ▼ 0% $2.88 ▼ $-3.258M ▼
Q2-2025 $0 $2.284M ▲ $-2.503M ▼ 0% $4.32 ▲ $-2.497M ▼
Q1-2025 $0 $1.65M ▲ $-1.735M ▼ 0% $-0.26 ▼ $-1.722M ▼
Q4-2024 $0 $23.242K ▼ $-31.139K ▲ 0% $-0.19 ▲ $-23.236K ▲
Q3-2024 $0 $8.036M $-11.851M 0% $-1.15 $-8.014M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $9.243M ▲ $11.614M ▲ $4.637M ▼ $6.977M ▲
Q2-2025 $3.466M ▼ $5.797M ▼ $5.677M ▼ $120K ▼
Q1-2025 $6.152M ▲ $8.308M ▲ $5.722M ▼ $2.586M ▲
Q4-2024 $1.187M ▼ $2.863M ▼ $6.852M ▼ $-3.989M ▲
Q3-2024 $1.973M $3.087M $7.666M $-4.579M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.262M ▼ $-2.843M ▼ $0 ▲ $8.624M ▲ $5.778M ▲ $-2.843M ▼
Q2-2025 $-2.503M ▼ $-2.507M ▼ $-1K ▲ $-195K ▼ $-2.689M ▼ $-2.508M ▼
Q1-2025 $-1.735M ▲ $-2.453M ▲ $-6K ▼ $7.432M ▲ $4.963M ▲ $-2.459M ▲
Q4-2024 $-1.747M ▲ $-2.926M ▼ $0 ▲ $2.184M ▼ $-753K ▼ $-2.926M ▼
Q3-2024 $-11.86M $-2.653M $-16K $2.92M $276K $-2.669M

Five-Year Company Overview

Income Statement

Income Statement Silexion is still a pure research-stage biotech with no product sales yet, so its income statement is driven almost entirely by research and corporate expenses. Operating results show early-stage losses from running the lab and the business, which is typical at this point in the lifecycle. The headline earnings per share figures bounce around sharply because they are based on very small absolute amounts and one‑off items, not on a steady business. In practical terms, the income statement today tells you this is a company investing in science, not one generating recurring revenue or profit.

Balance Sheet

Balance Sheet The balance sheet is very light, reflecting a small, early-stage operation. Assets are minimal and have at times been largely made up of cash or cash-like items. There is effectively no financial debt, which reduces balance-sheet risk but also underlines that funding relies on equity and external capital rather than borrowing. Shareholders’ equity has moved from positive to negative and back again, showing how sensitive it is to small gains, losses, and capital raises. Overall, the balance sheet is thin and highly dependent on continued access to funding as the company scales its trials.

Cash Flow

Cash Flow Cash flow is modestly negative, driven by spending on operations such as research, staff, and overhead, with little to no outlay on long-term physical assets. Free cash flow is therefore also negative, which is exactly what you would expect from a clinical-stage biotech building out its programs. The key takeaway is that Silexion is consuming cash rather than generating it, and future trial expansion will likely increase that cash burn. The company’s ability to secure fresh capital or partnerships will be critical, because internal cash generation is not yet part of the picture.

Competitive Edge

Competitive Edge Silexion is trying to carve out a focused niche in one of the toughest areas of oncology: KRAS‑driven solid tumors, especially pancreatic cancer. Its edge lies in a proprietary, localized RNA interference delivery system (LODER and SIL‑204) that aims to silence cancer‑driving genes directly inside the tumor, rather than targeting the protein in the bloodstream. This approach is differentiated from the more common small‑molecule drugs developed by large pharmaceutical players and could allow broader coverage of KRAS mutations. The company has some first‑mover advantages in localized RNAi for pancreatic cancer and a strategy to be used alongside standard treatments, which could support adoption if results remain strong. However, it competes in a crowded and well-funded landscape with large pharma companies, and its moat depends heavily on the strength of its clinical data, regulatory progress, and the defensibility of its delivery technology and patents.

Innovation and R&D

Innovation and R&D Innovation is the core of Silexion’s story. The company is built around its RNAi delivery platforms, aiming to silence KRAS mutations that have historically been considered very difficult to drug. The first‑generation product has already produced encouraging mid‑stage trial results in pancreatic cancer, and the second‑generation SIL‑204 platform is designed to be more potent, longer‑lasting, and easier to administer. Silexion is also pursuing a dual approach: direct injection into tumors and, with a partner, a potential systemic version for metastatic disease. The pipeline strategy targets not just pancreatic cancer but potentially other KRAS‑driven cancers like lung and colorectal, and a broader range of KRAS mutations. All of this means R&D spending will remain the central use of resources, with the company’s future hinging on whether upcoming toxicology work, pivotal trials, and formulation advances translate into clear and reproducible clinical benefits.

Summary

Silexion is an early, clinical‑stage biotech where almost all of the story is about science and future potential rather than current financial performance. The company has no commercial revenue, a very lean balance sheet, and ongoing cash burn to fund research and clinical work, all of which are typical at this stage but mean financial results will likely remain volatile and hard to interpret in the near term. Its value proposition rests on a specialized RNAi platform targeting KRAS‑driven cancers, with a strong focus on pancreatic tumors and a differentiated intratumoral delivery technology that could set it apart from systemic small‑molecule competitors. The opportunity is significant if its approach proves effective and scalable across multiple cancers and mutations, but the usual biotechnology risks—clinical, regulatory, funding, and competition from much larger players—are substantial. For observers, the most important things to track going forward are progress and outcomes in the key SIL‑204 trials, expansion into additional indications, the success of systemic delivery efforts, and the company’s ability to secure partnerships and capital to support its long development path.

NEWS

November 26, 2025 · 7:30 AM UTC

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Read more

November 25, 2025 · 9:15 AM UTC

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer

Read more

November 12, 2025 · 9:00 AM UTC

Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more

September 30, 2025 · 8:40 AM UTC

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

Read more

September 30, 2025 · 5:40 AM UTC

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

Read more